Resident Owned OM Medispa

Now offering the "skinny shot"

OM Medispa is owned and operated by Dr. Savitha Susarla who has been a resident of Thornwood 18 years with her husband and two kids. Dr. Susarla got started in the business because she sensed a need for an all inclusive wellness center and wanted to provide helpful and honest services in a community she loves. During the past 18 years she and her team have helped people with weight loss, hormone replacement therapy and even provide aesthetic services. Dr. Susarla has been very successful with the "skinny shot" and will provide a free consultation for anyone interested in learning more. 

Semaglutide and tirzepatide have emerged as promising options for weight loss in individuals struggling with obesity or overweight. Here's an in-depth look at how these medications are used, who might benefit from them, and important considerations:
Semaglutide and Tirzepatide for Weight Loss:
  • Mechanism of Action: Both semaglutide and tirzepatide belong to a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). They work by mimicking the effects of incretin hormones, which regulate insulin secretion, glucose metabolism, and appetite.
  • Administration: Semaglutide is typically administered once, while tirzepatide is also administered once weekly. The dosage may vary depending on individual response and tolerability.
  • Efficacy: Clinical trials have shown that both semaglutide and tirzepatide can lead to significant weight loss in participants with obesity or overweight. Semaglutide has demonstrated an average weight loss of 14% to 17% of initial body weight, while tirzepatide has shown an average weight loss of around 13% to 15% of initial body weight.
  • Duration of Treatment: The duration of treatment with semaglutide or tirzepatide may vary depending on individual weight loss goals and healthcare provider recommendations. Some individuals may benefit from long-term treatment to maintain weight loss.
  • Side Effects: Common side effects of both medications include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. These side effects may diminish over time with continued use.
Who Might Benefit:
  • Obesity or Overweight: Semaglutide and tirzepatide are generally recommended for individuals with a body mass index (BMI) of 30 or higher (obesity) or a BMI of 27 or higher with obesity-related comorbidities (such as type 2 diabetes, hypertension, or dyslipidemia).
  • Failure of Other Weight Loss Methods: These medications may be considered for individuals who have not achieved adequate weight loss with lifestyle modifications (such as diet and exercise) alone.
  • Health Considerations: It's important to consult with a healthcare provider to determine if semaglutide or tirzepatide is appropriate, especially for individuals with other health conditions or taking other medications.
Semaglutide and tirzepatide represent promising options for weight loss in individuals with obesity or overweight. They offer effective and well-tolerated treatments that may help address the growing global health concern of obesity-related complications. However, it's important to consult with a healthcare provider to determine the most appropriate treatment plan based on individual needs and health status.
If you are interested in learning more about how you can look and feel your best this summer,  Dr. Susarla provides free consultations with personalized service.